Salzburg Therapeutics


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, a...Show all

Company (Alive / Active)

Phone:

Fax:

3455 University Parkway
Winston-Salem, 27106
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Salzburg Therapeutics $0M Nov 30, 2018
See all 21 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Salzburg Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

PTC Therapeutics

South Plainfield, New Jersey, United States
IPO / Went publicPTC Therapeutics (PTC) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC has assembled technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and d...Show allLogin to see details
See all 21 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)